What's Happening?
Vanda Pharmaceuticals has announced the start of the Thetis study, a clinical trial aimed at evaluating the efficacy of NEREUS™ (tradipitant) in preventing vomiting among patients undergoing treatment with glucagon-like peptide-1 (GLP-1) receptor agonists.
These agonists, including semaglutide and tirzepatide, are widely used in managing type 2 diabetes and obesity but often cause gastrointestinal side effects like nausea and vomiting. These side effects are significant enough to lead to treatment discontinuation or dose reduction. The Thetis study is a multicenter, randomized, double-blind, placebo-controlled trial focusing on patients who begin treatment with a high dose of a GLP-1 receptor agonist. The primary goal is to determine the proportion of patients who remain free from vomiting episodes during the treatment period. Previous studies have shown that NEREUS™ can significantly reduce vomiting and nausea, with a Phase 2 study indicating a 50% reduction in vomiting episodes among participants treated with tradipitant compared to those on a placebo.
Why It's Important?
The initiation of the Thetis study is crucial as it addresses a major barrier in the effective use of GLP-1 receptor agonists, which are pivotal in treating type 2 diabetes and obesity. The gastrointestinal side effects associated with these drugs can severely impact patient adherence and quality of life, potentially limiting the therapeutic benefits. By potentially mitigating these side effects, NEREUS™ could enhance patient compliance and allow more individuals to benefit from these treatments. This development is particularly significant given the recent FDA approval of a high-dose version of Wegovy, which, while offering additional weight-loss benefits, also increases the frequency of nausea and vomiting. If successful, the Thetis study could lead to broader acceptance and use of GLP-1 therapies, improving outcomes for patients struggling with diabetes and obesity.
What's Next?
Vanda Pharmaceuticals expects to release topline results from the Thetis study by the fourth quarter of 2026. Depending on the outcomes, additional data may be required before a New Drug Application (NDA) can be submitted for NEREUS™. The results of this study could influence future regulatory decisions and potentially lead to expanded indications for NEREUS™. Stakeholders, including healthcare providers and patients, will be closely monitoring the study's progress, as its success could significantly impact treatment protocols for diabetes and obesity. The pharmaceutical industry may also see increased competition and innovation in developing adjunct therapies to improve the tolerability of GLP-1 receptor agonists.
